Khasawneh H, OBrien C, Czeyda-Pommersheim F, Qayyum A, Miller F, Arif Tiwari H
Abdom Radiol (NY). 2024; .
PMID: 39710762
DOI: 10.1007/s00261-024-04749-z.
El Homsi M, Alkhasawneh A, Arif-Tiwari H, Czeyda-Pommersheim F, Khasawneh H, Kierans A
Abdom Radiol (NY). 2024; .
PMID: 39643732
DOI: 10.1007/s00261-024-04732-8.
Korsic S, Osredkar J, Smid A, Steblovnik K, Popovic M, Locatelli I
Radiol Oncol. 2024; 58(4):517-526.
PMID: 39365794
PMC: 11702893.
DOI: 10.2478/raon-2024-0052.
He Z, Zhang X, Zhang Y, Kong J
Front Pharmacol. 2024; 15:1413696.
PMID: 39108743
PMC: 11300282.
DOI: 10.3389/fphar.2024.1413696.
Xu Y, Bai R, Zhang Q, Zhang S, Zhang J, Du S
Discov Oncol. 2024; 15(1):220.
PMID: 38858234
PMC: 11164853.
DOI: 10.1007/s12672-024-01083-0.
Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitor.
Lin P, Hsu Y, Kao Y, Teng W, Hsieh Y, Chen W
Am J Cancer Res. 2024; 14(3):1306-1315.
PMID: 38590407
PMC: 10998751.
DOI: 10.62347/GFVP1262.
Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma.
Hu Y, Pan T, Cai X, He Q, Zheng Y, Huang M
J Gastrointest Oncol. 2023; 14(4):1837-1848.
PMID: 37720446
PMC: 10502547.
DOI: 10.21037/jgo-23-486.
Predicting post-resection recurrence by integrating imaging-based surrogates of distinct vascular patterns of hepatocellular carcinoma.
Meng X, Tang T, Zhou Y, Xia C, Xia T, Shi Y
JHEP Rep. 2023; 5(9):100806.
PMID: 37575884
PMC: 10413153.
DOI: 10.1016/j.jhepr.2023.100806.
Breakthroughs in Hepatocellular Carcinoma Therapies.
Singal A, Kudo M, Bruix J
Clin Gastroenterol Hepatol. 2023; 21(8):2135-2149.
PMID: 36813012
PMC: 10293061.
DOI: 10.1016/j.cgh.2023.01.039.
Transarterial Chemoembolization with Anthracyclines-Loaded Polyethylene Glycol Drug Eluting Microspheres for the Treatment of Hepatocellular Carcinoma: A Pooled Multicentric Analysis of Survival in 580 Patients.
Gomes F, De Baere T, Verset G, Coimbra E, Tovar-Felice G, Malagari K
Cardiovasc Intervent Radiol. 2023; 46(4):436-446.
PMID: 36764953
PMC: 10060327.
DOI: 10.1007/s00270-023-03362-9.
Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment.
Zhu L, Zhang X, Xu S, Hu M, Zhao Z, Zhao G
Front Immunol. 2023; 13:1111246.
PMID: 36700197
PMC: 9868629.
DOI: 10.3389/fimmu.2022.1111246.
A systematic review of [Ga]Ga-DOTA-FAPI-04 and [F]FDG PET/CT in the diagnostic value of malignant tumor bone metastasis.
Li L, Hu X, Ma J, Yang S, Gong W, Zhang C
Front Oncol. 2022; 12:978506.
PMID: 36439440
PMC: 9686276.
DOI: 10.3389/fonc.2022.978506.
Pulsed Microwave Liver Ablation: An Additional Tool to Treat Hepatocellular Carcinoma.
Zanus G, Tagliente G, Rossi S, Bonis A, Zambon M, Scopelliti M
Cancers (Basel). 2022; 14(3).
PMID: 35159014
PMC: 8833939.
DOI: 10.3390/cancers14030748.
Long Term Survival Analysis in a Cohort of 125 Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using Small Drug Eluting Beads.
Cascella T, Garanzini E, Lanocita R, Morosi C, Riva F, Greco G
Cardiovasc Intervent Radiol. 2021; 45(1):54-61.
PMID: 34820694
DOI: 10.1007/s00270-021-02991-2.
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A
J Hepatol. 2021; 76(3):681-693.
PMID: 34801630
PMC: 8866082.
DOI: 10.1016/j.jhep.2021.11.018.
Metal-Regulatory Transcription Factor-1 Targeted by miR-148a-3p Is Implicated in Human Hepatocellular Carcinoma Progression.
Lyu Z, Yang M, Yang T, Ma M, Yang Z
Front Oncol. 2021; 11:700649.
PMID: 34660270
PMC: 8511627.
DOI: 10.3389/fonc.2021.700649.
Transcatheter Arterial Chemoembolization with Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma: Recommended Selection for Small-Caliber (<100 μm) Beads.
Chang W, Hsu H, Chiu S, Huang W, Lo C, Lin H
J Hepatocell Carcinoma. 2021; 8:937-949.
PMID: 34422707
PMC: 8373306.
DOI: 10.2147/JHC.S319920.
A Nomogram Based on Combining Clinical Features and Contrast Enhanced Ultrasound LI-RADS Improves Prediction of Microvascular Invasion in Hepatocellular Carcinoma.
Zhou H, Sun J, Jiang T, Wu J, Li Q, Zhang C
Front Oncol. 2021; 11:699290.
PMID: 34307168
PMC: 8297520.
DOI: 10.3389/fonc.2021.699290.
Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression.
Zou X, Fan W, Xue M, Li J
Cancer Manag Res. 2021; 13:4013-4029.
PMID: 34040442
PMC: 8142557.
DOI: 10.2147/CMAR.S304591.
An overview of hepatocellular carcinoma with atypical enhancement pattern: spectrum of magnetic resonance imaging findings with pathologic correlation.
Kovac J, Ivanovic A, Milovanovic T, Micev M, Alessandrino F, Gore R
Radiol Oncol. 2021; 55(2):130-143.
PMID: 33544992
PMC: 8042819.
DOI: 10.2478/raon-2021-0004.
